深度测序检测的微小残留病阴性是多发性骨髓瘤的主要预后因素
该研究基于一项评估移植在新诊断多发性骨髓瘤患者中作用的临床试验,用二代测序在维持治疗期间检测微小残留病(MRD),阴性定义为100万个骨髓细胞中无肿瘤浆细胞(<10^-6)。127例患者(25%)在维持期间至少一次达到MRD阴性;维持治疗开始时MRD阴性对无进展生存和总生存均为强预后因素,且不受治疗组、细胞遗传学风险或诊断时ISS分期影响。
要点
- 维持治疗期间127例(25%)至少一次达到MRD阴性(<10^-6)。
- 维持开始时MRD阴性者无进展生存 adjusted HR 0.22(95%CI 0.15-0.34,P<.001)。
- 维持开始时MRD阴性者总生存 adjusted HR 0.24(95%CI 0.11-0.54,P=.001)。
核心结论
- 研究结果证实二代测序确定的MRD状态是多发性骨髓瘤的预后生物标志物,并提示该方法可用于未来临床试验中调整治疗策略。
研究设计与样本
- 研究基于一项近期临床试验的数据,该试验评估移植在新诊断多发性骨髓瘤患者中的作用,患者接受来那度胺、硼替佐米和地塞米松(RVD)治疗。
- 采用二代测序在维持治疗期间检测MRD,MRD阴性定义为100万个骨髓细胞中无肿瘤浆细胞(<10^-6)。
主要发现
- 127例患者(25%)在维持治疗期间至少一次达到MRD阴性。
- 维持治疗开始时,MRD阴性对无进展生存的校正风险比为0.22(95%CI 0.15-0.34,P<.001)。
- 维持治疗开始时,MRD阴性对总生存的校正风险比为0.24(95%CI 0.11-0.54,P=.001)。
- 无论治疗组(RVD vs 移植)、细胞遗传学风险特征或诊断时国际分期系统疾病分期如何,MRD阴性患者获得延长无进展生存的概率均高于可检测残留病患者。
- 维持治疗完成后,结果相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (<10-6). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; P < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; P = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
引用
- Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018. PMID: 30249784. doi:10.1182/blood-2018-06-858613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。